Product Description
E-8001 is an intravenously administered drug candidate from Eisai. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04609852?term=E-8001&draw=2&rank=1)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location:
Company CEO: Haruo Naito
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04609852 |
E8001-J081-001 | P1 |
Completed |
Healthy Volunteers |
2023-08-18 |
4% |
2023-09-26 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/27/2023 |
PubMed |
Delayed nasoseptal flap reuse in patients with revision endoscopic endonasal anterior skull base surgery. |
|
05/07/2020 |
PubMed |
Rapidly Developing Methicillin-Resistant Staphylococcus Aureus Pericarditis and Pericardial Tamponade. |